CSL Ltd Annual Report 2020

Unified by our Values Throughout the pandemic period, the majority of our employees have continued to work on our sites and in our laboratories carrying out roles that are critical to ensuring our business continuity. For many others in our workforce, it has meant working remotely and adopting new technologies to ensure our culture of collaboration continues as we prepare for the safe return to our office sites. Through this challenging environment, our employees have stayed focused while demonstrating creativity, flexibility and resilience in continuing to do their jobs and doing themwell. Our people remain unified by our Values of Patient Focus, Innovation, Integrity, Collaboration and Superior Performance and we sincerely thank them for their commitment. Using our assets to join the COVID-19 battle We are privileged to be in a unique position of having capabilities, competencies and assets across the organisation to respond to COVID-19. These efforts range from participating in the development and manufacture of a novel vaccine in partnership with the University of Queensland, to forming and leading an unprecedented global industry alliance to develop a hyperimmune treatment for the most serious cases. Our scientists involved in these programs are working with urgency and we thank them for their tireless commitment over the past fewmonths. During the COVID-19 pandemic, a few hundred of our employees have tested positive for the virus. They, along with their loved ones, have had our full support as they focus on their recovery. Seeing so many people affected by COVID-19, over the past several months, makes us even more determined in our efforts to fight the virus. Yet, no single vaccine or therapeutic approach is going to solve this health crisis; multiple approaches are essential. We remain optimistic that the extraordinary amount of scientific collaboration happening across industry, academia and government, including many initiatives we are proud to be a part of, will lead to effective treatments and vaccines in the near future. Until that time, we are greatly encouraged by the fast adjustments that our business has been able to make to adapt to changing conditions, and help us endure any impacts of the pandemic. We are confident that from the pandemic crisis, society will eventually discover many benefits arising from it, ranging across the acceleration and adoption of new technologies, a deep resilience and ability to recover by the community, and a significant contribution to science and medicine. Board Renewal One of the Board’s priorities is to ensure it has the capabilities and domain expertise to govern our complex, global business effectively. We welcomed two new Board members, Carolyn Hewson and Pascal Soriot, and farewelled Tachi Yamada. We are excited to have Carolyn and Pascal join our Board as they will further contribute to the right balance of attributes, skills, experience and diversity to deliver best practice governance. Not only do we take a structured and rigorous approach to Board succession, we apply this level of review throughout the organisation to make sure that we have an agile, best in class and principles-based management team reflecting our Values. We are proud that external stakeholders recognise this with Forbes including CSL in its Best Employers for Diversity rankings 2020. We believe that we are well-positioned to bring our strategy for the future to life. Our continued momentumwould not be possible without the remarkable efforts of our people, our donors, our external partners and, of course, our patients. As always, we thank you for your support. Please stay healthy and safe. Dr Brian McNamee AO Paul Perreault Chairman CEO and Managing Director More on CSL.com (Investors > Financial Results and Information) CSL Limited Annual Report 2020 3